Collegium Pharmaceutical, Inc (COLL): Operating Cash Flow
$329.32M
Year ended 2025-12-31
$329.92M
Trailing 12 months to 2026-06-30
+38.4%
3-year compound annual growth
+28.5%
5-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $329.32M | +60.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $204.98M | -25.4% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $274.75M | +121.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $124.23M | +20.0% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $103.56M | +10.2% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $93.94M | +238.1% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $27.78M | -83.6% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $169.39M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$67.02M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$75.05M | n/m | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | -$21.57M | n/m | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | -$17.95M | n/m | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | -$16.53M | n/a | 2016-03-18, From 2013-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $329.32M | +60.7% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $142.00M | -28.4% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $170.60M | +190.6% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $179.55M | n/m |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $151.99M | -19.7% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $156.12M | -26.8% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $47.33M | -72.5% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $348.20M | +58.4% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $185.22M | +189.3% |
Compare COLL, CORT, EBS, ARWR side by side · Screen every company in Pharmaceutical Preparations ↗